Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema-Reply.
Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland2Editor, JAMA Ophthalmology.
Neil M
NM
Bressler
Jaeb Center for Health Research, Tampa, Florida.
Adam R
AR
Glassman
Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor5Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor6College of Engineering, Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.
David W
DW
Hutton
D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D003930:Diabetic Retinopathy; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema; D056687:Off-Label Use; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab